Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs

Medical Care

Volumn 46, Issue 4, 2008, Pages 394-402

  Alexander, G Caleb ^a,b,c,d,f   Zhang, James ^a,c,e   Basu, Anirban ^a,c  

^a Department of Medicine

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

Out of pocket costs; Pharmaceutical samples; Pharmacoeconomics

Indexed keywords

ARTICLE; CHRONIC DISEASE; DRUG INDUSTRY; FEE; FEMALE; HEALTH INSURANCE; HUMAN; INSURANCE; MALE; MARKETING; METHODOLOGY; MIDDLE AGED; PATIENT; PATIENT COMPLIANCE; SOCIOECONOMICS; STATISTICS;

CHRONIC DISEASE; DRUG INDUSTRY; FEES, PHARMACEUTICAL; FEMALE; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MALE; MARKETING; MIDDLE AGED; PATIENT COMPLIANCE; PATIENTS; SOCIOECONOMIC FACTORS;

EID: 41149103830     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181618ee0     Document Type: Article

References (19)

1. Prescription drug trends. Kaiser Family Foundation. November 2005. Fact Sheet 3057-04.
2. Wolf BL. Drug samples: benefit or bait? JAMA. 1998;279:1698-1699.
3. Holmer AF. Industry strongly supports continuing medical education. JAMA. 2001;285:2012-2014.
4. Christie JD, Rosen IM, Bellini LM, et al. Prescription drug use and self-prescription among resident physicians. JAMA. 1998;280:1253-1255.
5. Boltri JM, Gordon ER, Vogel RL. Effect of antihypertensive samples on physician prescribing patterns. Fam Med. 2002;34:729-731.
6. Backer EL, Von Tonder RJN, Crabtree BF. The value of pharmaceutical representative visits and medication samples in community-based family practices. J Fam Practice. 2000;49:811-816.
7. Groves KE, Sketris I, Tett SE. Prescription drug samples-does this marketing strategy counteract policies for quality use of medicines? J Clin Pharm Ther. 2003;28:259-271.
8. Medical Expenditure Panel Survey (MEPS). Available at: http://www.meps.ahrq.gov/. Accessed on May 19, 2006.
9. Cohen J. Design and methods of the Medical Expenditure Panel Survey Household Component Rockville, MD: Agency for Health Care Policy and Research; 1997. MEPS Methodology Report No. 1. AHRQ Pub. No. 97-0026.
10. Basu A, Rathouz P. Estimating marginal and incremental effects on health outcomes using flexible link and variance-function parameters. Biostatistics. 2005;6:93-109.
11. Basu A, Arondekar BV, Rathouz P. Scale of interest versus scale of estimation: comparing alternative estimators for the incremental costs of a comorbidity. Health Econ. 2006;15:1091-1107.
12. Hurwitz MA, Caves RE. Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals. J Law Econ. 1988; 31:299-320.
13. Rizzo RA. Advertising and competition in the ethical pharmaceutical industry: the case of antihypertensive drugs. J Law Econ. 1999;42:89-116.
14. Bound J, Jaeger DA, Baker RM. Problems with instrumental variables estimation when the correlation between the instruments and the endogeous explanatory variables is weak. J Am Stat Assoc. 1995;90:443-450.
15. Bawa K, Shoemaker R. The effect of free sample promotions on incremental brand sales. Mark Sci. 2004;23:345-363.
16. Urban G, Hauser J. Design and Marketing of New Products. Englewood Cliffs, NJ: Prentice Hall; 1993:341-342.
17. Gonul FF, Carter F, Petrova E, et al. Promotion of prescription drags and its impact on physicians' choice behavior. J Mark. 2001;65:79-90.
18. Alexander GC, Casalino LP, Meltzer DO. Physician strategies to reduce patients' out-of-pocket prescription costs. Arch Intern Med. 2005; 165: 633-636.
19. Alexander GC, Tseng CW. Strategies to identify and assist patients burdened by out-of-pocket prescription costs. Cleve Clin J Med. 2004; 71:433-437.